Wai Chun Bio-Technology Expects Fiscal 2026 Profit of at Least HK$ 30 Million

PUBT · 2d ago
Wai Chun Bio-Technology Expects Fiscal 2026 Profit of at Least HK$ 30 Million
  • Wai Chun Bio-Technology expects profit of at least HK$ 30 million for the year ended June 30, 2026.
  • The turnaround from a roughly HK$ 10.7 million loss in fiscal 2025 reflects a one-off HK$ 52.1 million impairment reversal.
  • The property, plant and equipment reversal reflects significantly improved operating performance and outlook for the modified starch business.
  • A roughly HK$ 15 million reversal of deferred tax assets partially offsets the gain.
  • Annual results are expected November 13, 2026; shares remain suspended pending publication, having halted trading October 2, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wai Chun Bio Technology Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261111-12408334), on November 11, 2026, and is solely responsible for the information contained therein.